drugset

Drugs / AURN001

Follow last change 10 days ago re-read 3 minutes ago

AURN001

Developed for: bullous keratopathy · Fuchs' endothelial dystrophy
Investigated by: Aurion Biotech

Trials 1

today NCT07368959 · Ph 3

2027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 3	NCT07368959	Feb 2026 → Jun 2027 expected	Fuchs' endothelial dystrophy, bullous keratopathy	Aurion Biotech	Recruiting	No outcome recorded

News releases announcing trial results or a regulatory action · 4

Date	Issuer	Release
2025-10-18	Aurion Biotech	Results Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months aurionbiotech.com ↗ Aurion Biotech , a clinical-stage regenerative medicine company with a mission to restore vision to millions of patients, today announced positive 12-month results from the company’s Phase 1/2 CLARA trial, which evaluated the safety, efficacy and tolerability of AURN001
2024-12-17	Aurion Biotech	Results Aurion Biotech Announces Positive Topline Data for Phase 1/2 Clinical Trial of AURN001, an Allogeneic Cell Therapy Product Candidate for the Treatment of Corneal Edema Secondary to Corneal Endothelial Dysfunction aurionbiotech.com ↗
2024-06-25	Aurion Biotech	Regulatory Aurion Biotech Receives Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation for Its Drug Candidate AURN001 aurionbiotech.com ↗
2023-05-02	Aurion Biotech	Results Aurion Biotech to Present Clinical Trial Results at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting aurionbiotech.com ↗ Escalon data are consistent with our previous trials showing clinically meaningful improvements in central corneal thickness and best corrected visual acuity.

All press releases naming this drug 6 releases

Date	Issuer	Release
2026-09-23	Aurion Biotech	Aurion Biotech Completes Enrollment in Pivotal ASTRA Phase 3 Study, Advancing AURN001 Toward Potential New Treatment for Corneal Edema Secondary to Corneal Endothelial Dysfunction aurionbiotech.com ↗
2026-04-08	Aurion Biotech	Aurion Biotech Doses First Patients in ASTRA Phase 3 Study, Evaluating AURN001 in Patients with Corneal Edema Secondary to Corneal Endothelial Dysfunction aurionbiotech.com ↗
2025-10-18	Aurion Biotech	Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months aurionbiotech.com ↗
2024-12-17	Aurion Biotech	Aurion Biotech Announces Positive Topline Data for Phase 1/2 Clinical Trial of AURN001, an Allogeneic Cell Therapy Product Candidate for the Treatment of Corneal Edema Secondary to Corneal Endothelial Dysfunction aurionbiotech.com ↗
2024-06-25	Aurion Biotech	Aurion Biotech Receives Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation for Its Drug Candidate AURN001 aurionbiotech.com ↗
2023-05-02	Aurion Biotech	Aurion Biotech to Present Clinical Trial Results at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting aurionbiotech.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	AURN001	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07368959 ↗
Route	Other	“AURN001 will be injected to the anterior chamber of the eye.” NCT07368959 ↗